Let’s start up with the current stock price of ACADIA Pharmaceuticals Inc. (ACAD), which is $21.28 to be very precise. The Stock rose vividly during the last session to $21.775 after opening rate of $20.61 while the lowest price it went was recorded $20.61 before closing at $20.60.
Recently in News on April 14, 2021, HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys, Firm Investigating ACAD for Possible Securities Law Violations. San Francisco, California–(Newsfile Corp. – April 14, 2021) – Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims. You can read further details here
ACADIA Pharmaceuticals Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $55.85 on 01/08/21, with the lowest value was $20.12 for the same time period, recorded on 04/12/21.
ACADIA Pharmaceuticals Inc. (ACAD) full year performance was -52.64%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, ACADIA Pharmaceuticals Inc. shares are logging -63.76% during the 52-week period from high price, and 5.77% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $20.12 and $58.72.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2816810 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the ACADIA Pharmaceuticals Inc. (ACAD) recorded performance in the market was -60.19%, having the revenues showcasing -60.28% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 3.45B, as it employees total of 601 workers.
Market experts do have their say about ACADIA Pharmaceuticals Inc. (ACAD)
During the last month, 12 analysts gave the ACADIA Pharmaceuticals Inc. a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 6 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 45.03, with a change in the price was noted -34.01. In a similar fashion, ACADIA Pharmaceuticals Inc. posted a movement of -61.51% for the period of last 100 days, recording 1,799,660 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ACAD is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of ACADIA Pharmaceuticals Inc. (ACAD)
Raw Stochastic average of ACADIA Pharmaceuticals Inc. in the period of last 50 days is set at 3.55%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 14.16%. In the last 20 days, the company’s Stochastic %K was 7.34% and its Stochastic %D was recorded 4.21%.
Bearing in mind the latest performance of ACADIA Pharmaceuticals Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -60.19%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -50.65%, alongside a downfall of -52.64% for the period of the last 12 months. The shares increased approximately by 0.24% in the 7-day charts and went up by -29.04% in the period of the last 30 days. Common stock shares were lifted by -60.28% during last recorded quarter.